Business Context and Reporting Period
Company: The Joint Corp. (JYNT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: The Joint operates and franchises chiropractic clinics across the United States. The company is currently executing a strategic shift to re-franchise or sell the majority of its company-owned and managed clinics to private equity firms and existing franchisees, aiming to leverage its franchise-building capacity for long-term growth.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 |
|---|---|---|
| Total Revenues | $30.20 million | $90.18 million |
| Net Loss | $(3.17) million | $(5.81) million |
| Loss Per Share (Diluted) | $(0.21) | $(0.39) |
| Adjusted EBITDA | $2.43 million | $8.07 million |
| Cash and Cash Equivalents | $20.74 million | $20.74 million (as of Sept 30) |
| Debt (Credit Agreement) | $0 | $0 (Paid down in Jan 2024) |
| Assets Held for Sale | $25.33 million | $25.33 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 2.5% ($0.72 million) for the quarter and 3.6% ($3.1 million) for the nine months compared to the prior year periods. This growth was driven by the expansion of the franchise base (838 clinics vs. 778 in 2023) and increased royalty fees, offset by a slight decline in company-owned clinic revenues due to divestitures.
- Operating Loss: The loss from operations widened significantly to $3.19 million for the quarter (vs. $0.90 million loss in 2023) and $5.59 million for the nine months (vs. $1.93 million loss in 2023). This deterioration is primarily attributed to a $3.81 million net loss on disposition or impairment in the quarter, largely related to the re-franchising strategy and asset write-downs.
- Expense Trends: General and administrative expenses increased by $3.43 million for the nine months, driven by $1.5 million in litigation settlement costs (employment matters) and increased professional fees related to the CEO search. Depreciation and amortization decreased by 39.6% due to the cessation of depreciation on assets classified as held for sale.
- Cash Flow: Net cash provided by operating activities decreased to $5.28 million for the nine months ended Sept 30, 2024, compared to $11.29 million in the prior year, primarily due to the absence of a $4.8 million Employee Retention Credit (ERC) refund received in 2023.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects to continue the re-franchising of company-owned clinics, marketing them in clusters to private equity firms. Approximately 60% of the corporate clinic portfolio is expected to close within one year. Proceeds are intended for capital allocation opportunities, including brand reinvestment, IT platforms, and potential stock repurchases.
- Liquidity: The company holds $20.7 million in cash and has $20 million available under its revolving credit facility. Management believes these resources are sufficient to fund operations for the next 12 months.
- Key Risks:
- Litigation: Ongoing mediation regarding a medical injury claim with a potential settlement range of $0.9 million to $6.0 million (currently accrued at $0.9 million, offset by insurance).
- Leadership Transition: CEO Peter D. Holt resigned in October 2024; Sanjiv Razdan was appointed as the new CEO. A separation agreement accrual of $0.6 million was recorded.
- Macroeconomic Factors: Inflation, labor shortages, and rising interest rates continue to impact operating costs and patient discretionary spending.
- Internal Controls: The company has previously identified material weaknesses in internal controls over financial reporting.
Investor Verification Checklist
- Re-franchising Execution: Verify the progress of selling company-owned clinics and the actual cash proceeds realized versus the estimated fair value of $19.5 million.
- Litigation Resolution: Monitor the outcome of the medical injury claim mediation to determine if the $0.9 million accrual is sufficient or if additional costs will be incurred.
- Adjusted EBITDA Quality: Review the reconciliation of Net Loss to Adjusted EBITDA, noting the significant add-backs for impairment losses ($5.6 million for nine months) and litigation expenses ($1.5 million).
- Debt Covenants: Confirm continued compliance with the Credit Agreement covenants, particularly given the recent leadership changes and operating losses.
- Internal Control Remediation: Assess the status of remediation efforts for previously identified material weaknesses in internal controls over financial reporting.